



eh


exercise ; cardiovascular system
hz
follow-up
reporting ; cell ; Anand
doxorubicin
doctors ; blood transfusions


molecular mechanism
dXA
heart failure
FM
Liver disease

hz
exercise ; cardiovascular
Renal artery stenosis

surgery ; heart transplant recipients


tertiary referral
heart beat

heart failure ; Latin America


HF

environment


doctors


Heart rate
Nutrition ; heart failure
northwest united states
heart failure
surgery
Cross-sectional


Heart failure


clin
trans

Jehovah ; witness ; anemia
exercise

dodson

CHF

frailty
competitive
autonomic balance
LV fibrosis
treatment ;HFpEF

ST2
Heart failure ; cognitive impairment
department of cardiology ; hospital
follow-up
HF ;HF
hospital ; heart failure
medical conditions
frailty ;HF
co
cardiac transplantation
cognitive function
Heart rate variability ; cardiac
taxonomy

Sham-operated animals


policy
compliance ; treatment

Heart failure ; uk
CHF
air pollution ; heart failure

cardiovascular disease
hz ; MI

Heart failure ; disease
hemostasis

remote ischemic conditioning ; heart failure
Heart failure ; bisphosphonates
right heart failure ; pulmonary hypertension
Caspase-3 gene expression ; heart failure
diuretic ; heart failure
functional capacity


hypertension
HF
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure

etiology ; MR ; ms
HFpEF
ejection fraction ; bNP
Pigs ; antiarrhythmic medication
beta blockade
CHF ; intubated
circulatory arrest
functional capacity
collected ; systolic dysfunction
internal reliability ; cronbach

frailty ; heart failure


implanted monitoring devices

conditions
HR ; ea ; afterload
strokes
RAS ; atherosclerosis
exercise ; heart failure
microRNAs ; heart failure ; disease management
Hazard ratios ; cox regression
psss ; exercise
heart failure ; ejection fraction
Cardiology ; bromodomain inhibition ; heart failure
heart failure ; cardiovascular death
mitral stenosis ; medical ; treatment ; heart failure
vasopressin ; congestive heart failure
Trastuzumab-related cardiotoxicity ; breast cancer
Medication ; sST2

mortality ; sts ; hm
pde2 ; hz
hospital
Heart failure ; public health
albumin level
lVET ; aortic pressure curve
physician continuity
arrhythmia-related costs ; expenditures
Devices ; cornerstone of heart failure ;HF ; therapy
Cardiac symptoms
spironolactone ; systolic heart failure
eRK ; molecular scaffolds ; heart pathology
functional MS ; MR
chronic heart failure ; bisoprolol
Heart failure ;HF ; society
cox
Tolvaptan ; vasopressin


propensity

black patients

metric ; readmission metrics
mechanism ; ET ; CHF
readmission metric
HF
residual confounding

follow-up
heart failure
mortality
cardiac ; inflammatory biomarkers
hz ; cardiovascular
baseline ; HRQol
ejection fraction outcomes trial
biomarkers ; chronic heart failure
Seattle ; Heart Failure model
cox
kidney injury
multiorgan failure ; sepsis
Psychometric testing ; Self-Care of Heart Failure index
nordic walking ; heart failure
heart failure ; cox
baseline ; heart failure
Pharmacological ; acute heart failure
ms ; surgery ; echocardiography
Hemodynamic ; Fontan
Coronary angiography
dialysis ; implantation
off-pump ; sparing ; HeartMate II exchange
VO2max
exercise

HR ;HF
ESRD
AIN oUTCOME ; tug test
biomarkers
drug ; japan

heart failure
healthcare

cardiac




Heart failure ; left ventricular ejection fraction
HR variability ; cardiac death
change
chronic kidney disease ;CKd
lead ; hypertension ; kidney failure
Readmission ; hospital ; heart failure
keletal muscle abnormalities ; exercise capacity ; Fontan circulation
physical ; heart failure
systolic HF
AIN oUTCOME

medication ; hemodynamics
postsystolic function
lVAD implantation

income ; expenditure ; health per capita
mice ; aac ; cardiac hypertrophy
AHA ; ESC

hz
heart failure
stand-alone diagnostic devices ;HF
heart failure
acute heart failure
toxicity ; blood pressure
circulation
cPGs
north America



ms ; surgery
endothelial function

hz ; chromatin hyperacetylation
diagnostic ; filling
health ; medicare

public reporting
sinus rhythm ; AF
heart failure ; cardiac rehabilitation
Race ; spironolactone ; heart failure
Myocardial infarction ; Wistar rats

benefits ; anemia treatment ; heart disease

rate-control

treatment ; post- lVAD AI
AI
acute heart failure

QRs



mortality
deficit index
gls ; cv
ms ; surgery

anaerobic threshold ; heart failure
renin-angiotensin-aldosterone system inhibitors ; heart failure
CHF ; unilateral renal DNx ; cardiac autonomic balance
mitral regurgitation ; hz ; surgery
compliance ; attrition
Heart block ; induced ; pulmonary artery snared ; BiVP
inflammation ; metabolism ; heart
CAD ; systolic ;HF
diuretic ;HF
cardiovascular events
bioinformatic ; genes ; heart failure
af ; echocardiographic examination
MS
heart lesions

PVf ; recovery ; pb
economic ; accounting ; cost
nurses
sST2 ; BB therapy
ms ; hz ; ms
ICU ; mortality
Cardiac function ; pressure-volume conductance catheter system
ct ; dialysis-dependent patients
beta-blockers
CHF
RM
hz
cardiomyopathy ; mortality
unfolded protein response ; cardiac sodium current ; systolic ; heart failure
diastolic dysfunction ; peripheral artery disease
western blot ; immunohistochemistry ; electron microscopy
angiotensin receptor ; neprilysin inhibitor ; heart failure
evidence ; dilated cardiomyopathy
hypertensive LV dysfunction ; ms
hypoalbuminemia ; heart failure
etiologies
ms ; surgery
exercise training ;ET ; endothelial function
fm ; FM ; stable body weight ; CC
coronary disease ; heart failure
medical ; cardiovascular
dialysis
cardiac remodelling
heart transplant ; ecCT
hff
hHF ; dPP-4 inhibitors ; drugs
bundle branch block ; electrical activation sequence
southeastern Minnesota ; hh
Frailty ;HF
proteome ; HDl particles
heart failure
proteins ;TAC
Cardiac cachexia ; body composition
rehospitalization
exercise ; exercise
heart rate variation
cRF
DASh ; diet scores
diabetes ; eEO-cFUs
heart failure
Cardiac-resynchronization therapy ; heart failure
hospital-to-Home ; hospital ; readmission reduction ; congestive heart failure
hf ; hfpEF
physician ; death ; urgent readmission ; discharge ; heart failure
nitroxyl ; hno ; heart failure
change ; lVET ; follow-up measurement
odds ratios ; accounting
blacks ; VO2 ; baseline

aerobic exercise
hospitals
trastuzumab-related CHF
transplants
Peak VO2
hospitals
financiers

hz ; haemodynamic ; neuronal stressors
Heart failure ; rheumatoid arthritis ; tNF antagonist
mortality ;HF ; hospital admissions ; transplant ; ventricular assist device
Coronary artery disease ;CAD ; systolic heart failure ;HF
hypoalbuminemia ; lVAD ; surgery
holosystolic murmur ; heart
psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam
death ; non-fatal stroke ; heart failure
Renal artery stenosis ;RAS ; peripheral arterial disease
connected ; heart failure
subclinical atherosclerosis
Wilcoxon ; signed-rank tests
incidence ; ESRD ; outpatients ; hz
left ventricular assist device ; right ventricular
baseline ; eCGs ; electrocardiographers
right ventricular function ; heart failure
biological ; mortality
exercise intolerance ; chronic heart failure
heart transplantation ; left ventricular assist device
ect ; advanced heart failure therapy
atrial fibrillation ; af ; heart failure
Fat ; cachexia ; right ventricle ; heart failure
avd ; VVD ; free wall
mortality
renal denervation ; autonomic balance ; rabbits ; chronic heart failure
expression ; regulatory subunit ;RI ; hz
Pediatric heart failure ;HF
heart failure
heart failure ; ejection fraction
cPET ; exercise ; CHF
eplerenone
baseline ; ect ; cardiac transplant recipients
VEGF inhibition ; cardiac function
Heart failure ;HF ; cardiovascular
technique ; exchange malfunctioning ; HeartMate II lVADs
extubated ; blood loss ; transfusion
recovery

β-blocker ;bb ; sST2
bromodomain proteins
miRNAs ; cardiac pathogenesis
medications ; heart failure
mortality ; iCD-HF
septal defects
mlh
coronary heart disease ; stroke ; heart failure
mortality rate
bt ; dt ; implantation
heart failure ; readmission
ST2 ; plasma
hz
biomarkers ; treatment ;HF
hypotension

condition ; economic
CAD ; CAD
renal dysfunction ; post-transplant morbidity
lVAD implantation
Cardiac hypertrophy ; energy metabolism
pn assessment ; ED
trastuzumab
treatment
Renal DNx ; circulating plasma ; CHF-inv rabbits
Heart failure disease ; medical
germline DNA
HDL-bound malondialdehyde
HF
blood work ; medication
anemia ; heart disease

hospital discharge
hospitals

readmissions ; follow-up visits ; heart failure ; readmission quality
Myxomas ; right atrium ; pulmonary arterial vasculature
Orthotopic heart transplantation ; oHT ; treatment ; heart failure
right atrial myxoma ; pulmonary embolism ; right heart failure
nafat ; mir-25 ; transcription factor ; hand2 ; heart failure
resistin ; ejection fraction
Framingham Heart study ; hf ; EF
coronary artery disease ;CAD
diuretics ; heart failure ;HF
radiological ; hf
east ; rhythm control therapy ; cardiovascular complications ; AF
Cardiac overexpression ; Mammalian ; mena ; heart failure
lVAS ; bridge to transplantation ; therapy
canine model ; chronic heart failure ; tachycardia
pump ; driveline ; injury ; pump replacement
cps ; functional capacity ; VO2
evidence-based therapies ; fes
Nicorandil ; doxorubicin
heart failure
eh ; hpEF
ischemic ; abdominal ; MT
evidence ; aCP
medline ; epacse ; ciinahl
ed ; intubations ; congestive heart failure
acr ; CMS
HF
hh ; saxagliptin ; sitagliptin
heart failure ; health ; body composition
band of activated Caspase ; paced myocardium
Heart ; heart failure ; arrhythmias
evidence
implantation ; ct
world health organization ; hf ; la

degs ; osprey
change

Medicare ; post-acute care transfer policy

ed ; CHF
deficit index
nuts ; mortality

iron
benefit ; β-blocker uptitration ; hpEF
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
QT intervals ; SD ; QT intervals ;SDQT
bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
remote monitoring ; hospital discharge ; heart failure
right ventricular contractile reserve ; pulmonary hypertension
baseline ; echocardiograms ; reverse remodeling
Soluble ST2 ; ambulatory patients ; heart failure
LV ; filling pressure ; severe systolic HF
Titin hypophosphorylation ; myocardial
atrial fibrillation ; pacemaker
technique ; myocardial fibrosis
medical ; heart failure ; Canadian Cardiovascular society
psychosocial factors ; exercise ; heart failure ;HF
cardiac catheterization ; extubated
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis
compliance
HRQol ; exercise ; baseline hgb
NOc ; admission ; discharge
cardiac resynchronization therapy ; heart failure
active
inpatient records ;HF
report ; aRIC HF
skeletal muscle mass ; VO2
ees ; ventricular-arterial coupling ; SV
pneumonia ; conditions
autonomic nervous system activity ; QTV
diastolic failure ; cardiomyopathic ; flow
cardiovascular
mortality predictors ; iCD-HF
myocardial tissue ; pka
body mass index ; cRF ; treadmill exercise testing
AF-free ; catheter ablation ; sinus rhythm
disease ; paediatric cardiac transplants
thics Rounds

exercise ; diet
white


renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
anemia ; heart disease ; american college of Physicians
biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
renal disease ; systolic heart failure
Heart Failure ; Pathophysiology ; medical
rvpo ; BiVP ; RS synchrony
parasympathetic neurotransmission ; acetylcholinesterase inhibition
echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
exercise ; chronic heart failure ; lipoprotein
cardiovascular death ; hz ; exercise training ; btes
acute autonomic nervous system modulation ; QTV ;HF
resistin ; cardiotoxicity
Myocardial pde2 ; expression ; activity ; hz

Heart rate ; aortic blood flow ; doxorubicin
BAT ; sympathetic outflow ; parasympathetic activity
treatment ; congestive heart failure ;CHf
heart
left pulmonary artery ; pulmonary artery
breast cancer ; cardiotoxicity
cps ; diabetes
DASh ; diet scores ; mortality ; heart failure ; women ; health Initiative
LVEF ; long-term mortality
dobutamine ; furosemide ; oxygen flow
miRNAs ; heart failure
Jehovah's Witness ; sickle cell disease ; anemia
mri ; baseline ; heart failure
health Buddy program ; ed

l-type ca2+ currents ; rad ; congestive heart failure
physician continuity ; conditions ; hospital discharge
defense mechanism ; cardiac stress ; β-AR drive
psss ; btes ; exercise
heart failure
health outcomes
muscle-wasting syndrome ; acquired heart failure ; Fontan
health Buddy program ; telehealth system ; care management
bisoprolol ; mortality
ed ; CHF ; intubation rates
Medicare
t test ; confidence intervals ;CIs
myocardial diastolic dysfunction
systolic ; diastolic mitral leaflet ; organic lesion
doppler echocardiography ; pulmonary hypertension
circulating progenitor cells ; heart failure
LV ; strain rate ; echocardiography ; baseline ; ablation
co ; septal wall ; avd ; free wall ; VVD
etiologic ; acute rv failure ; left ventricular dysfunction
biventricular pacing ; left heart ; twist ; right heart failure
transplantation ; circulatory assist device
hz
cps ; functional capacity ; heart failure ; hz
ctnt ; NT-probNP ; hh
inhibition of protein kinase ; guanylate cyclase ; contractile
HR ; beta blockers ; exercise capacity ; hFrEF
activity ; i-mig ; myocardial washout
Canada
cardiopulmonary ; exercise ; heart failure
mortality ; bnp ; mortality
radiological ;HF
costs ; heart failure ;HF
right ventricle ;rv ; cardiac function ; medical
Mortality ; aCS ; operation
RV dysfunction ; weight loss ; fat ;lean body mass ratio
transcatheter ; surgery
beta blockers ; mortality ; heart failure
pd ; refractory ; end-stage congestive heart failure ;CHf
HF ; valve plasty ; ms ; mva
pressure ulcers
baseline ; ST2 ; interquartile range
death ; heart failure
diagnostic ; fluid overload
outcome change scores ; heart failure
black race ; mortality
insurance ; comorbidities
chemotherapy-induced heart failure ; breast cancer

NYHA
chelation regimens ; heart iron
MT ; consultation ; abdominal
Time up ; go test ; chronic organ failure
diagnoses
follow-up
mortality
monitoring board
ejection fraction ; cardiac resynchronization therapy ; heart failure
surgery ; aortic valve insufficiency ; left ventricular assist device implantation
ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
pacing-induced dilated cardiomyopathy
right atrium mass ; prolapse ; tricuspid valve ; stenotic
California ; office of statewide health planning and development ; Patient discharge
cardiac catheterization ; thrombotic obstruction ; right coronary artery
echocardiographic ; invasive hemodynamic
hff ; sodium restriction ; ventricular ; vascular stiffness
functional capacity ; mwt
chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
CHF ; atrial explants ; sham explants
magnetically Levitated left ventricular Assist system ; hz
Font failure ; systolic ventricular function ; liver disease
Heart failure ; society ; cardiovascular diseases

extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
protein ; western blot ; DNA fragmentation ; tunel ; autopsy samples
eh ; cardiac filling pressures
implantable ; cardioverter-defibrillator deactivation
herbal medicine ; dilated cardiomyopathy ; heart failure
trastuzumab ; cardiac
mechanistic ; electromechanical delay ; dyssynchronous heart failure
cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
economic ; af ; heart failure ; Québec ; Canada

bundle-branch block ;LBb ;LBb
BETs ; TAC ; hz
systolic function
flow-mediated dilatation ; ET
cp ; hz
cox regression ; cardiovascular events ; psoriasis
heart failure ; protein kinase ; expression
cutoff ; NT-probNP
dopamine ; nesiritide strategy
Seattle Heart Failure
HF
aHF
nitrite
neurological ; cardiovascular
MAD-ct

transfusion thresholds ; mortality
Czech republic
cardiac nurses


heart failure
health
preoperative serum albumin ; left ventricular assist device implantation
western blots ; monoclonal antibodies ; ser83 phosphorylation ; hz
HRQol
interleukin receptor ; ST2 ; beta-blocker therapy ; chronic heart failure
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
echocardiography ; baseline ; shunt implantation
exercise intolerance ; heart failure ; exercise
ms ; ring annuloplasty ; MR ; LV
New York Heart association
pathophysiology ; hz ; medical
vasopressin receptor antagonist ; tolvaptan ; heart failure
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
cox models ; ST2
ed ; New Jersey ; New York
TM ; sts
psoriasis ; smoked ; diastolic blood pressure ; body mass index
ecmo ;VAD ; ecmo+VAD
inotropic effect ; beta blockers ; heart failure
anticoagulation ; heart disease ; rate control
mortality ; morbidity ; cancers ; budget
energy metabolism ; heart failure ; hypertrophied heart
NT-probNP ; circulation ; hh
HR ; ivabradine ;TAC ; ea
PAD ; ankle-brachial index
MS ; dynamic ; ms
baseline ; mechanical cardiac ; renal function
renal dysfunction ; mechanical cardiac
implanted
left ventricular dilatation
evidence ; anemia ; heart disease
CF lVAD ; AI ; heart failure
baseline ; rhythm-control ; rate-control
heart failure ; systolic heart failure
HF ; epidemiology ; health service ;HF ; la
functional MS ; medical ; treatment ; surgical
hemoglobin levels ; health
ventricular assist devices
Heart failure ;HF ; chronic disease
heart failure ;HF
serum factors ; coagulability
exploratory factor ; cFA
pb ; hf ; primary oscillations ; pattern generator

computing ; readmissions
iCD

HF
pro-adrenomedullin ;MR-proADm ; fm
Cardiorespiratory ; body mass index ; heart failure mortality ; Cooper center longitudinal study
bNP ; NT-probNP ; biomarkers ; heart failure

receptors ; adenylyl cyclase ; differential g-protein coupling
heart failure ;HF ; left ventricular ejection fraction ; hpEF
circulating fragments ; natriuretic peptides ; plasma ; heart failure
ejection fraction ;EF ; infarct ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
rial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
physical ; cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
ATP ; demand ;ROS ; mitochondrial respiration ; contractile function
implantable cardiac defibrillator
heart failure ; implantation ; ventricular assist device
systolic HF ; etiology ; coronary angiography
hg ; cardiac murmurs ; blood pressure ; hg
exercise intolerance ; chronic hff ; qol
isoproterenol ; cXL-1020 ; myocytes ; hearts
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
instability ; heart failure ; ventricular tachycardia
treatment ; cardiac angiogenesis ; coronary perfusion ; cardiac fibrosis
biventricular dysfunction ; isolated HeartMate II
hz ; vt ; beat-to-beat ;QT
social mandate ; accountable
pressure-overload ; heart failure
tug test ; COPd ; CHF ; cRF
procedure ; hemodynamically unstable ; cPR
ecmo ; egFR ; egFR
sonographic ; histological ; gastrointestinal
aCS ; MT ;VAD
HR ; tNF ; nbDMARD
Rotterdam ; psoriasis ; cardiovascular outcomes
evidence ; schfi
energy substrate metabolism ; working hearts ; aac
cvd ; psoriasis
diabetes mellitus ; cardiovascular ; baseline
rule ; CAD ; CAD
general hospital ; cardiac specialty hospital ; south dakota
exercise ; haemodynamic
medical records
diagnostic ; rule
cachexia ;RV function ; body composition
cognitive impairment ; mortality
hospital length ; rehospitalization
hospital mortality
hz ; outline
administration ; trastuzumab-related CHF

hospitals

cardiac death
mechanical cardiac ; renal function ; end-stage heart failure
functional mitral stenosis ; ring annuloplasty ; mitral regurgitation
heart transplantations ;LV ; implantations ; heart failure admissions
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
mouse ; hh ; transition ; LV hypertrophy ; hh
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
natriuretic peptide ; biomarkers
sympathetic ; parasympathetic activity ; hz
bNP ;PAD ; bNP ; hz
Spironolactone ; hyperkalemia ; kidney injury
chronic myocardial ischemia ; heart failure
eh ; systolic blood pressure ; renal impairment ; hypertension
HFpEF
exercise ; hz
parasympathetic function ; hz
Heart failure ;HF ; condition
jugular venous pressure ; peripheral oedema
medical ; hz ; hz ; ms ; mva
baseline ; hgb ; exercise ; kccQ
medical revascularization ; catheter-based revascularization
pump-exchange technique ; sternotomy ; cardiopulmonary bypass
derive ; rule ; CAD ; systolic HF
Morpholino-based knockdown of nucleolin ; protein expression
ms ; medical ; ms ; dynamic ; medical
cardiovascular conditions ; hz
Cytoscape ; DAVID
blacks ; hypertension ; diabetes ; etiology ; socioeconomic ; whites
cutoff value ; NT-probNP testing ; ED ; acute heart failure
health insurance ; health system ; u.s. Food and Drug administration
isolated lVAD
Fontan circulation ; sVR index ; cardiac index
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
hereditary ; congenital abnormalities ; heart ; nontraumatic death
mineralocorticoid receptor antagonists
albumin levels ; lVAD
isolated HeartMate II lVAD
evidence-based
bisphosphonate ; heart failure
right heart circulation ; right heart failure
Raf-MEK1/2-ERk1/2
MI ; late-onset ; MI ; hz
emd
costs
sustainability


diagnose ; heart failure ; preserved ejection fraction ; doppler echocardiography
Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac
spironolactone ; systolic heart failure
beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
myocardial ischemic events ; cardiac resynchronization therapy
β-Blockade ; cardiac angiogenesis ; heart failure ; veGF
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
HF ; preserved ejection fraction ; hpEF ; hypertension
heart failure ;HF ; Heart Failure adherence and retention trial ;HAR
hpEF ; breathlessness ; fatigue
Myocardial infarction ; left anterior descending coronary artery occlusion
NYha ; functional class
report ; aortic valve surgery ; post- lVAD
immunodetection ; NT-probNP ; antibodies
unloading ; heart ; isolated HR reduction ; systolic heart failure
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
oxidative stress ; GTPase Rac1 ; activity ; hearts ;ANS mice
medications ; outpatients ; heart failure ; NCDR PINnaCLE
cardiovascular death ; cardiac transplant ; death
circulating mediator of insulin resistance ; monocytes ; inflammatory
Heart failure ;HF ; Latin America ; lha ; health service planning ;HF
Heart failure ; medicine ; atheromatous coronary disease
palliative ; disease
hz ; ct ;hazard ratio
rehospitalization ; medicare
diagnostic test ; hpEF ; medical ; physical



readmission rate
psoriasis ;UV
ischemic ; ischemic heart failure
conditions ; heart failure
art failure ; Emergency department ; ed ; ed
Intravenous iron ; heart failure ; iron deficiency
RV dysfunction ; weight loss ; body composition ; hz
pd ; complications ;HF
diastolic dysfunction ; hFPEF
Chromatin-associated proteins ; chromatin ; DNA ; gene expression profile
NT-probNP ; hz ; immunoprecipitation ; mass spectrometric
right ventricle ; overload leads ; stroke volume ; ventricular ejection time ;VET
β-Adrenergic receptor blockade ; heart failure ;HF
congestive heart failure
mitochondrial ; sarcomeric
CHF ; emergency department ; ed ; intubated
mortality ;LCx ;LAD
pp ; acr ; CMS
gut ; inflammation ; heart failure ; heart failure
heart failure ; ejection fraction
robot-assisted gait therapy ; Lokomat ; heart failure
abm ; implantable ; cardioverter-defibrillator deactivation
pulmonary hypertension ; heart failure
lVET ; death ;ICU
exercise ; hemodynamic
Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
HDl function ; CHF-NYha-IIIb ; HDl function
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
CHF ; activated neurohormonal systems
heart rate ; renal function ; spironolactone
evidence ; microRNAs ;miRNAs ; heart failure
Beta-blocker ; hz ; bpm
QT variability ; QTV ; QTV ; cardiac death
New Zealand ; white rabbits ; renal DNx ; CHF
ambulatory HF ; ventricular ejection fraction
paradigm-HF ; chronic heart failure ; Chronic heart failure ; cardiology
follow-up ; discharge ; readmission ; heart failure
dialysis ; echocardiographic
zSF1 ; heart failure ; ejection fraction
transoesophageal echocardiography ; thrombosis ; migration
line ; mutant mice ; hand ; heart muscle cells ; pathological hypertrophy
Cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
arterial tonometry ; VET ; precapillary PH ; heart failure
heart magnetic resonance imaging ; chelation choices ; compliance ; heart disease ; thalassaemia
mri ; tidal respiration ; myocardial ; swine ; heart failure
advantage ; POc technology
costs
cardiovascular disease ; baseline
Rhythm control therapy ; side effects

readmissions
AMI mortality rates
psoriasis ; cardiovascular disease ; cvd
cutoff ;septal
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cardiomyocytes
cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
Hemoglobin ; exercise ; heart failure
RAS-blocker uptitration ; hFrEF ; hfpEF
Myocardial collagen ; phosphorylation
Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
diastolic dysfunction ; filling pressures ; doppler echocardiography
cardiovascular disease ; dRS

medical ; hf
miRNAs ; cardiac remodeling ; heart failure
frailty ; heart failure ; hz
heart failure ; bisphosphonates

cardiomyocytes ; norepinephrine-induced hypertrophic
index admission ; index admission
Plasma samples ; hh
alendronate ; alendronate ; heart failure
transduction pathways ; proteins
baseline ; HR
GDt ; control group ; GDt ; BAT
heart failure ; CLcnka sNP
diastolic dysfunction
aCS ; oHT ; transplant ; MT ;VAD

regulation of feeding ; anti-inflammatory effects ; CHF
financiers ; hh ; CMS ; conditions
expression ; Bax ; bcl-2 proteins
hf ; rheumatoid arthritis ;RA
β-Blocker-induced enhancement ; cardiac angiogenesis ; cardiac function
Fontan ;SAF ; catheterization
natriuretic peptides
alphaLISa ; immunoassays ; NT-probNP
cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
heart failure ; left ventricular ;LV ; ejection fraction
implantable ; cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
death ; biological phenotype
drugs ;HF ; ejection fraction ; hrEF
diastolic dysfunction ; figure ; mechanism ; hf
ambulatory iCD ; mortality
fes ; ejection fraction ; hpEF
Myxomas ; cardiac benign tumors
nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
Gastrointestinal bleeding ; ventricular assist devices
arni inhibitors ;angiotensin-receptor neprilysin inhibitors
Renal denervation ; dnx ; CHF
follow-up ; discharge ; physician continuity ; heart failure
hyperkalemia ; kidney ; spironolactone
Heart failure ; preserved ejection fraction ; hf ; cardiovascular reserve
heart failure ; left atrial pressure ; hospital admission
Mammalian enabled ; mena ; regulator ; cytoskeletal actin dynamics ; heart failure ; hz
refractory congestive heart failure ; peritoneal dialysis
MT ; VAD ; aCS ; operations
bNP ; NT-probNP ; coronary artery disease ;CAD

aerobic capacity ; left-hand grip ; waist circumference
ect
NT-probNP
exercise
functional mitral stenosis ; ms ; ring annuloplasty ; ischemic mitral regurgitation ;MR
heart failure-related hospitalization ; left ventricular ejection fraction
Kansas City ; Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
heart failure ; preserved ejection fraction ; hbff
lean ; zSF1 ; hypertensive ; zSF1 ; diabetic
doppler imaging ; left ventricular filling pressure ; systolic heart failure
Heart failure ; preserved ejection fraction ; hpEF ; cardiovascular morbidity
myocardial pde2 ; intracellular antiadrenergic ; hz
ICU ; admission ; precapillary PH ; heart failure
Myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
transfusions ; heart disease
PVf ; pb ; BP
sST2 ; cardiovascular
ecg ; ct
remote monitoring ;RM ; heart failure
RV dysfunction ; cardiac cachexia
chronic heart failure ; Hungary
HF
combination ; exercise ; diet ; peak VO2 ;joint effect
spironolactone ; medications
carotid ; intima-media ; psoriasis
coronary occlusion ; collateral growth ; stent occlusion
mechanical dyssynchrony ; QRs ; ct
pharmacologic
ie ; heart failure ; hz ; death ; ct-d
breast cancer ; trastuzumb-related CHF
pde2 ; hearts
guideline ; heart disease
point-of-care systems ; np ; ed ; outpatient settings ; acute heart failure
eEO-cFUs ; mortality ;hazard ratio
trastuzumab ; CHF ; nontrastuzumab
egFR ; diuretics ; hypertension ; ESRD
heart failure
acute heart failure ; aHF ; heart failure ;HF
psoriasis ; disease ; atherosclerosis ; cardiovascular ; psoriasis
hz ; emd ; dyssynchronous failing heart
HR ; beta-blocker therapy
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
surgery ; medical ;HF ; hypertension ; vasodilators ; diuretics
aldosterone antagonist ; heart failure
angiogenesis ; post-myocardial infarction heart ; heart failure
heart failure ; ejection fraction ; myocardial infarction
lVAS
HDl function ; CHF ; eth
HF ; risk factors ; HF mortality
hz ; cPGs
hff
exercise ; cardiac disease ; heart failure
black race ; hz ; cardiovascular mortality
coronary artery disease ; systolic heart failure ; etiology
ea ; arterial compliance ;TAC ; end-systolic elastance ; ees ; baseline
Renal dysfunction ; cardiovascular events ; primary isolated caBG
baseline ; isoprenaline infusion ; SDQT ; hNorm ;HF
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hpEF
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ; caBG
cardiovascular ; HeartMate II lVAD ; centriMag rVAD ; mortality
Pyridostigmine ; vascular endothelial growth factor ; left ventricle ; myocardial angiogenesis
Shunt implants ; transseptal catheterisation
dopamine ; nesiritide

biomedical ; nonprescribing
ERC ; epicatechin ; muscle function
technology ; health outcomes ; Medicare
baseline ; ea ; TAC ; HR ; ees
HF ;HF
CHF ; international Classification of Diseases
medline ; epac ; cochrane ; clinical trial registries ; technical
egFR ; VAD ; ecmo ;VAD ; ecmo
idiopathic dilated cardiomyopathy
cardiac ; chromatin remodeling
Robot-assisted gait therapy ; Lokomat® system ; heart failure
baseline ; cRF ; HF mortality risk ; HF ; risk factors
RV dysfunction ; body mass index ; fat mass index ; cachexia
myocardium ; expression ; pka ; downstream
elastic n2bus segment ; pevk
proteomics
cXL-1020 ; inactive ; cXL-1051
arterial elastance ; pulsatile afterload ; heart
pharmacologic ; acute HF ; chronic HF
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; mechanism of cardioprotection
HeartMate ; left ventricular assist system ; lVAS ; heart failure
grounded theory ; heart failure ; implantable ; cardioverter-defibrillator
Self-Care of Heart Failure index ; schfi ; psychometric profile
atrial fibrillation ; carvedilol ; metoprolol
heart failure ; mechanical ; cards-cardiovascular surgery Consensus report ; Heart failure
MIs ; Killip class ; conditions
end stage heart failure ; Heart failure ; public health ; europe ; north America
HeartMate II ; insertion ; HeartMate II implantation
functional MS ; valve plasty ; MR ; LV ; disease
tNF antagonists ; hf ; hospital admissions ; nbDMARDs ; RA
evidence
nurses
mortality
exercise ; exercise ; diet
grs ; cv
ejection fraction
epidemiology ; myocardial infarction ; mi ; heart failure ;HF
Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker
isoelectric ; RIα ; ser77 ; ser83 ; vivo phosphorylation
baseline
mADIt-ct ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
admission ; serum levels ; brain natriuretic peptide ; bnp ; creatinine ; natremia
RAS ; hypertension ; nephropathy ; congestive heart failure
SDt ; SD ; rr intervals ;SDr ; QTV ; heart rate
cardiac magnetic resonance imaging ; invasive hemodynamic assessments ; baseline
hf ; drug treatment ; PAf biosynthetic enzymes ; lyso-paf-AT
cardiac events
sST2 ;low-dose BB ; sST2 ; high-dose BB
hf ; am ; mortality
LV ; ejection fraction ; pcw
zebrafish ; nucleolin ; genomic reprogramming
physical ; mortality ; hz ; noncardiologist
CHF ; ED ; CHF ; intubated
Logistic regression models ; secondary outcome ; death
egFR ;VAD ; ecmo ;VAD ; renal function
aUCs ; eseptal ;septal ; QRs
gastrointestinal bleeding
hospital ; readmission rate ; heart failure
diuretics ; morbidity
readmission rate ; hospital ; congestive heart failure ; united states
IVc occlusion ; twist ; apical rotation ; RS ; RS synchrony
acute heart failure ; Collins
heart failure ;HF ; inpatient ; outpatient
carvedilol ; metoprolol ; heart failure
bet ; bromodomain-containing protein 4 ; rob4) ; cardiac tissues
costs ; Québec ; health insurance board ; costs ; Ontario case costing Initiative
report ; mitral valve plasty ; mitral regurgitation
intravenous iron ; exercise ; heart failure
erythropoiesis-stimulating agents ; anemia ; heart disease
public health ; air pollution ; cardiovascular health
molecular biomarkers ; pathophysiology ; chronic HF
cardiopulmonary exercise ; quality of life ; muscular strength ; peak quadriceps force
HF ;heart failure ; t2d ; type 2 diabetes ; Skm ;keletal muscle
Morbidity ; mortality ;HFpEF ;HF ; EF ; treatment
hz ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
idiopathic dilated cardiomyopathy ; tuscany
ecg ; ion channelopathies ; cardiomyopathy
RAS ; neprilysin inhibition ; change ; chronic heart failure ; systolic dysfunction ; treatment
AF ablation
ejection fraction
multiparametric echocardiographic ; ct
evidence gaps ; economic ; lVAD
end-stage heart failure ; mechanical cardiac
change ; follow-up
administration ; gadolinium-chelate contrast agent
Medicare ; admissions ; acute care hospitals ; united states
hz ; ejection fraction ; pEF
mouse ; hh ; salt loading ; uninephrectomy ; ANG II infusion
report ; DAPc ;dystrophin-associated protein complex ; sarcomeric ; baseline
dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; ROse ; acute heart failure
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat ; metabolic
Cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
If-channel inhibition ; hemodynamic ; exercise ; heart failure ; ejection fraction
rv ; diagnostic ; intrinsic left ventricular dysfunction
Chronic heart failure ; transforming growth factor ; functional ; atrial
Mortality ; inpatient admissions ; emergency department ; ed
hf ; MI ; ejection fraction ;EF
exercise ; heart failure
HeartMate II lVAD ; centriMag rVAD
HFpEF ; ccq ; health
baseline ; serum creatinine ; serum potassium level
pd ; weight loss ; diuretic
echocardiographic predictors ; cardiac resynchronization therapy ; crt
NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
university of Connecticut ; Heart Failure Center ; cardiologist ; heart failure
anemia ; chronic heart failure ;HF
Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes ; Retn
chromatin subproteomes ; heart failure ; mechanisms ; chromatin
nbDMARD ; tnf ; baseline covariates
hFrEF ; exercise ; HR ; bpm ; beta-blocker therapy
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic aCF
heart failure ; heart failure ; cardiology ; mortality
heart failure ;HF ; cardiopulmonary exercise ; anaerobic threshold
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
cox hazard models ; ESRD ; death ; ESRD ; death ; ESRD
RCts
pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
baseline ; PAf ; activity ; metabolic enzymes ; heart failure
trastuzumab ; cardiotoxicity ; congestive heart failure ;CHf
carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype
Phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
echocardiographic ; natriuretic peptide ; inflammatory markers
myosin binding ; protein-c phosphorylation ; ser23/24 troponin ; phosphorylation ; hz
uPR effectors ; protein kinase ; er kinase ; calreticulin ; chop ; hz
hf ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; left ventricle


CHF
costs
doxorubicin ; ip ; induction of serum resistin levels ; Hum-retn mice
pigs ; vena cava ; icc ; snared ; co
surgery ; rheumatic ; MS ; surgery ; mva
post-hCT CHF ; hCT ; City of Hope
cardiac deaths ; atherosclerotic CAD
Peak oxygen consumption ; oxygen pulse
dialysis-dependent ;HF ; ct implantation
rv ; pathophysiologic mechanisms ; RV dysfunction
infarcted animals ; left ventricle ; end-diastolic pressure ; hg ; scar
women ; health Initiative ; hh
economic ; NHs ; chronic disease ; exercise
aldosterone receptor antagonists ; systolic heart failure
non-fatal stroke ; heart failure
biomarkers ; molecular dysfunction ; chronic HF
Ambient air pollution ; cardiovascular health ; trigger ; acute myocardial infarction
VAD ; ecmo+VAD ; ecmo
Genes ; ischemic ; heart failure ; biomarkers ; heart failure
mAIN oUTCOME ; gls ; index beat method ; cv ; cox
ST2 ; discrimination
east ; rhythm control therapy ; af ; cardiovascular complications ; AF
hearts ; Mena ; cardiac injury ; Mena ; hh ; pathophysiology
scn5a ; uPR ; cardiac genes ; hz
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ; CC
cox ; health
tpse ; PASp ; downward regression line shift ; nonsurvivors ; PASp ; tpse
right ventricular ;RV ; left ventricular assist device ; lVAD
albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD implantation
kccq ; kaplan-meier curves ; death
Olmsted County ; Minnesota ; MI ; diagnosed ; hh
collected ; medical ; hh
rule ; CAD ; CAD
inhibition of vascular endothelial growth factor ;veg ; transition ; compensatory hypertrophy ; cardiac failure
left ventricular ejection fraction ; heart failure ; Heart failure Survey ; israel
neurohumoral blockers ; hh
odds ratio ;hazard ratio ; hh ;AMI ; admission
testosterone ; exercise rehabilitation ; chronic heart failure ; testosterone
health Buddy program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
RAS ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
icc ; multicenter Automatic Defibrillator implantation ; trial-Cardiac resynchronization Therapy
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
proteomics ; pathway ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
AMI ; heart failure ; kidney infection ;UTI
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD ; implantation
HR dynamics ; HR ; risk stratification
ct-d ; IE ; defibrillator-only therapy
diagnostic ; treatments
hz ; index AMI ; hazard ratio ; mortality
apoptosis ; pathogenesis ; heart failure
BETs ; transcriptional pause release ; pathological stress
evidence ; lVAD ; transplantation ; budget
LVEF ; LVEF
uPR ; mRNA splice ; cardiac ; hz
diuretic efficacy ; neurohormonal
ecg ; atherosclerotic CAD ; cardiac death
obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
cardiopulmonary exercise ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
coronary revascularization ; hemodynamically ;ICU
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
speckle tracking echocardiography ; ste ; BiVP ; right ventricular pressure overload ;rvpo
HR reduction
mice ; LV ; lung ; weight
functional enrichment ; programmed cell death ; degs
rad variant ; congestive heart failure
systolic heart failure ; spironolactone
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
perk inhibition ; full-length scn5a ; kv4.3 mRNA levels ; mRNA splice
bottleneck stent ; myocardial infarction ; antiplatelet medication
bNP ; hf ; bNP
atrial fibrillation ; af ; heart failure ; hz ; stroke ; anticoagulation
echocardiographic ; LV ; reverse remodeling
salt loading ; uninephrectomy ; ANG II infusion ; cardiac function ; hz
Mena expression ; hz ; Mena ; cardiac pathophysiology
LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
atrial fibrillation ; atrial fibrillation ; Stroke prevention trial
benefits
NP measurement ; POc measurement ;NPs
financial ; evidence ; intestinal morphology ; absorption function ; CHF
readmission rates
etiology ; comorbidities
expression ; cardiac hypertrophy ; nucleolin
peak work rate ; peak quadriceps force
myocardial ; dt ; muscle strip stiffness ; titin hypophosphorylation
arni ; cardiovascular mortality ; heart failure
exercise ; anaerobic metabolism ; respiratory
idiopathic dilated cardiomyopathy
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue ; histologic
Kansas City ; Cardiomyopathy Questionnaire ; kv ; hf ; EF ; hpEF
Blood pressure ; arm cuff ; stroke ; ejection fraction ; end-diastolic volume ; echocardiography
biventricular ; hybrid ; HeartMate II lVAD ; centriMag ; right ventricular assist device ; radVAD
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index of right ventricular contractile function
right ventricular ;RV ; body composition ; heart failure ;HF
american college of Cardiology ;American Heart association ;RAS ;RAS
heart failure ; hz
functional MS ; valve plasty ; annular size reduction ; MR ; LV ; dilated ; disease
implantable ; cardioverter-defibrillator deactivation ; heart failure
ee-cFUs ; vgFR2 ; functional capacity ; mortality ; nondiabetic
report ; functional MS ; valve plasty ; MR ; LV ; disease
exercise training ;HF ; exercise ; therapy
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
snp ; ka renal chloride channel ; ccnka
Circulating progenitor cells ; cps ; endothelial repair ; cardiovascular diseases
hz-action cohort ; baseline hgb ; baseline HRQol ; kccq
pathological remodelling ; heart ; cardiac hypertrophy ; hz ; death
NT-probNP levels ; dyspnea ; left ventricular dysfunction ; admission ; ED
contractile function ; LV dilatation ; end-diastolic pressure ;wall stress ; lung weight
LV ; diastolic ; XO inhibition ; heart failure
costs
borderline
blood pressure ; lipid-lowering ; smoking cessation ; foundation ;RAS
SDwt ; hnorm ; fixed-rate atrial pacing
bt ; dt ; bt
expenditure ; health per capita ; income per capita ; hz ; la
ct-d ; heart failure ; death
bn ; inhospital mortality
technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
af ; hff
RAS- ; β-blocker uptitrations ; hFrEF ; hfpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
diagnose ;HFpEF ; echo-doppler cardiography ; haemodynamic assessment
low-sodium DASh diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; heart failure
implantable cardioverter-defibrillators ; iccds ; cardiac resynchronization therapy ; crt
frail ; intermediate frail
hff ; cardiac event
LBb ; implantable ; cardioverter defibrillator-ct ; primary outcome
mdc
embryonic ; pathological heart disease ; transcription factors ; driving
acute heart failure ; aHF
RM ; discharged ; admission ; heart failure
skeletal muscle ; heart failure ; diabetes ; epicatechin-rich cocoa
QRs morphology ; cardiac resynchronization therapy ; crt
exercise-induced PASp ; hg ; PASp
sST2 ;low-dose ; sST2 ; high-dose ; cardiovascular events
mitochondrial complex ; activity ; post-aac ; ratio of phosphocreatine ; ATP
eplerenone ; hh-ref ; hyperkalemia ; wRF
centrifugal flow pump ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
physical ; medically managed diseases ; hz
isolated heart rate ;HR ; ivabradine ; systolic heart failure
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
cardiovascular ; Renal Atherosclerotic lesions ; coRAL ; stenting ;RAS
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; induce heart failure
multiparametric echocardiographic score ; reverse remodeling ; ct
Mediterranean and Dietary Approaches to stop hypertension ;DASh ; mortality ; postmenopausal ; hh
left-to-right interatrial shunting ; heart failure ; ejection fraction
mortality ; heart failure ; hz ; implantable cardioverter defibrillators ; iccds
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical ; heart failure
cardioprotective ; myocardium ; biomarker ; heart failure ; hz
cardiovascular death ; stroke ; heart failure ; myocardial infarction
MI ; metoprolol ; norepinephrine ; dopamine ; epinephrine
exercise-induced PASp ; pulmonary hypertension ; ventricular contractile reserve
implantable cardioverter-defibrillator ; Heart Function Clinic ; university health network ; toronto ; Canada
perk activation ; scn5a ; kv4.3 ; mRNAs ; transient receptor potential cation ; m7 ; tlp7) ; mRNA
Cardiac-resynchronization therapy ; cmt ; chronic systolic heart failure ; QRs
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
POc ;NP ; diagnostic
medical
functional capacity
electronic ; medline ;EMBAse ; PsycINFO
echocardiography ; cardiac diameters ; cardiac function
lb ; QRs ; implantable ; cardioverter ; defibrillator-ct
readmissions ; costs
international right Heart foundation ; step ; syndrome of right heart failure
HF ; risk factors ;HF ; epidemiology ; SH ; rheumatic fever
mice ; cardiac myocyte-specific Mena overexpression ; tgtetMena ; cardiac pathology
hpEF ; diastolic filling ; heart rate
medications ; heart failure ; ejection fraction
chronic heart failure ;HF ; hemodynamic disorder ; interconnected molecular pathways
caloric restriction ;diet ; aerobic exercise training ; exercise capacity ; QOL ; obese ; hff
antiplatelet agents ; anticoagulants ; vascular diseases
systolic HF ; cXL-1020 ; left ; right heart ; filling pressures ; systemic vascular resistance ; cardiac ; stroke
r. Cluster
follow up ; body weight ; FM ; fm ;cc
af ; heart failure ; financial burden
mice ; cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; ac
heart failure ; hospital discharge ; readmissions
intermacs ; interagency Registry for mechanically Assisted Circulatory Support
truncated na+ channels ; unfolded protein response ; ucp ; scn5a ; electric remodeling ; hz
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous HF
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sv ; cardiac index
allopurinol ; contractile ;ROS ; myofilament ; sensitivity
baseline ; hgb ; baseline ; kccQ ; hgb ; exercise ; HRQol
ventricular ejection fraction ; left ventricular diastolic end diameter
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ; hpEF
eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
isolated heart transplant ; ecCT
rate ratio ; treatment ; comorbidities
et ; molecular pathways ; chronic heart failure ; ghf
physical ; cRF ; hh mortality
metabolic exercise ; cardiac ; kidney index score
heart failure ; compliance ; etidronate ; alendronate
rehospitalization ; Medicare ; claims ; Medicare ; post-acute care transfer policy
physicians ; advanced heart failure
bn ; diastolic dysfunction
techniques ; systolic function ;HFpEF ; long axis function ; exercise
induced ; scn5a ; angII ; hypoxia ; expression ; induced ; uPR
NT-probNP assay ; nonterminal epitopes ; glycosylated
receptors ; g-protein-coupled receptor kinase-2
hz ; hyperkalemia ; hypokalemia ; spironolactone ; derive
hf ; mortality ; hazard ratio ; mortality
dopamine ; nesiritide ; renal function
follow-up ; etidronate ; raloxifene-treated
principal mechanisms ; diagnostic ; treatment
implantable ; cardioverter defibrillator-crt ;LBb
kccq ; internal ; hfpEF ; ronbach
guideline ; anemia ; iron deficiency ; MEDline ; cochrane Library
hART ;HFpEF ;HF ; ejection fraction ; hrEF
bone morphogenetic protein ; expression ; rRNA transcription ; shift
left ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
systolic HF ; Danish Heart Failure ; ESRD ; Danish Registry on Dialysis
extracellular matrix ; left ventricular biopsies ; tissueFAXs ; technology
elevated resistin ; anthracycline-induced cardiotoxicity ; heart failure
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
ST2 ; natriuretic peptide
tachypacing-induced HF ; cXL-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
chemotherapy ; trastuzumab ; CHF ; international Classification of Diseases ; healthcare ; common procedure coding system codes
heart failure ;HF ;HF ; left ventricular ejection fraction ;LVEF

sST2 ; high-dose BB ; sST2 ; low-dose BB ; cardiovascular
saxagliptin ; sitagliptin
myocardial collagen ; myocardial
Sprague-dawley ; sham ; aCF ; allopurinol
cardiac plasma membrane ; s1PR1 ; overstimulation ; heart failure
neurohormones ; adipokines ; body composition ;cc ; fat free mass ; fm ; fat mass ;FM
magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure ; PubMed
biventricular pacing ; biVP ; cardiac output ; cardiac surgery
Myocyte hypertrophy ; heart failure ; gene expression ; DNA
expression ; mistargeting ; regulation ; rad Q66p ; rGK protein
creatinine ; bnp ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
AlphaLISa immunoassays ; antibodies ; circulating ; NT-probNP
New York Heart association ; nyha ; chronic heart failure ; ejection fraction
catheter ablation ; af ; hff ; left ventricular ; ejection fraction
transplantation ; consultation ; operation
ct ; hazard ratio
cardiomyocytes ; mechanical ; humoral ; myocardium ; conditions
BB therapy ; sST2 measurement ; chronic heart failure ; BB
biventricular ; rVADs ; explanted
functional efficacy ; hno ; donor ; myocardial function ; evidence ; hz
tunel assay ; apoptotic cells ; tunel-positive cells
pip relationship ; length-force relationship ; step ; rv ; LV
ESRD ; systolic HF ; egFR
transitions ; readmission rate ; congestive heart failure ; midwestern state ; South dakota
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
transplantation ; LV ; implantation ; heart failure
race ; exercise training ; chronic heart failure ; Heart Failure ; exercise
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
intraclass correlation coefficient ; icc ; kappa coefficient ; change ; mdc
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
biological ; medical records
Cardiology ; national Cardiovascular Disease Registry ; Clinical Excellence
tachycardia ; intravenous atropine ; cardiac vagal tone
CHF ; cardiac explant
transitions of care
induced myocardial infarction ; heart failure ; bisoprolol
sts HH ; medical ; mortality ; discharged ; heart failure
Peritoneal dialysis ; pd ; diuretic ; overload ; heart failure ; hz
SDt ; hwt ; hNorm ; β-adrenoceptor blockade ; esmolol
heart failure ; preserved ejection fraction ; hf ; heart failure ; overweight
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Font circulation
readmission rates ; heart failure ; hz ; acute myocardial infarction ; am ; pneumonia
Peripheral artery disease ;PAD ; heart failure ;HF ;HF ;PAD
echocardiographic score ; reverse remodeling ; LV ; end-systolic volume
renal dysfunction ; heart failure ; hz ; renal disease ; erd
report ; hno donor ; cXL-1020) ; isolated myoctyes ; intact hearts ; heart failure ;HF

POc testing ;NP ; consultation ; ED
shuttle walk test ; body mass ; hand grip strength ; baseline
physician ; mortality ; internists ; cardiologists
histological ; capillary ; coronary perfusion
race ; chronic heart failure ;HF ; exercise
ms ; dynamic ; ms ; fixed ring
heart failure ; CHAr programme ; candesartan in Heart failure assessment of reduction in Mortality and Morbidity
left-to-right interatrial shunting ; heart failure ; ejection fraction ; proof-of-principle
heart failure ; left ventricular ejection fraction ; spironolactone ; Kaiser Permanente Northern California
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin ; cardiotoxicity
aldosterone antagonist therapy ; heart failure ; post-myocardial infarction ; heart failure
myocardial extracellular matrix ; cardiac magnetic resonance
physical ; bmi ; weight ; heart rate ; lying ; standing ; blood pressure ; auscultation ; valvular disease ; pulmonary congestion
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; coronary artery bypass grafting
troponin ; natriuretic peptide ; heart failure ; atherosclerosis
exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
Fontan ; pf ; catheterization
dyssynchronous nonfailing ; hz ; canine electromechanics
cell therapy ; chronic heart failure ;CHf ; disease
anemia ; HF ; health-related quality of life ; hQol ; HF
Lancet ; anoop Shah ; air pollution ; heart failure
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
american college of Physicians ; acp ; evidence ; anemia ; iron deficiency ; heart disease
cardiac transplant ; ect ; transplant pool ; transplant
septum ;systolic ; posterior wall ; internal diameter ; metoprolol
HR variability ; mortality ;AMI ; CHF ;LV
BAT ; n-terminal pro-brain natriuretic peptide ;HF
HF registry ; HF ; hpEF
economic ; Heart failure ; cost-effectiveness ; disease management ; heart failure
obese ; hff ; caloric ; aerobic exercise ; peak VO2
rv failure ; chronic pulmonary arterial hypertension ;PAh ; pulmonary embolism
baseline ; SDQT-to-SDr ratio ; hwt ; hwt
ventricular ; fiber ; sheet orientation
rad Q66p ; cardiomyopathy
sST2 ; cardiovascular event rate
serum resistin levels ; anthracycline-containing chemotherapy ; cardiotoxicity
rv ; pulmonary embolism ; mortality
exercise ; medical Therapies ; Cardiac Function ; Breath ; Lung congestion
tachycardic response ; methylatropine ; vagal tone ; bradycardic ; propranolol
mortality ; mortality ; cardiovascular mortality ; hz ; race ; cox models ; exercise
spironolactone ; death ; hyperkalemia ; kidney injury
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ;LAD
cardiac resynchronization therapy ; crt ; heart failure ; hz ; QRs ; ejection fraction
neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; natriuretic peptide
electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; left ventricular ejection fraction
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
herbal medicine ;CHm ; dilated cardiomyopathy ; dm ; heart failure
hypoalbuminemia ; albumin concentration
nurse ; cognitive impairment ; physician ; discharge ; heart failure
bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
Baroreflex sensitivity ; time domain ; heart rate variability ; hv ; CHF-inv ; sham-inv ; renal DNx
heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical
electrical activation ; dyssynchronous heart failure ; hz ; electromechanical ; heart
HF-action ;HF ; ejection fraction ; exercise training
hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
tpacse ; PASp relationship ; nonsurvivors ; hFrEF ; hfpEF ; resolution
in vivo inhibition ; mir-25 ; antagomir ; cardiac dysfunction ; murine myocardium ; heart failure
cardioprotective effect ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; doxorubicin
haematopoietic cell transplantation ; hCT ; congestive heart failure ;CHf ; hCT ; anthracyclines
NT-probNP ; mortality ; hz
epigenetic ; proteins ;histone acetyltransferases ;erasers ;histone deacetylases ; cardiac
carvedilol ; β-blocker ; β-blocker metoprolol ; thromboembolic events ; heart failure
baseline ; cardiac transplant ; ect
mortality
heart failure ;HF ;HF ;HF
arrhythmia substrate ; am ; HR ; arrhythmia events
doxorubicin-induced cardiotoxicity ; Hum-retn mice ; littermate ; resistin ; retn
hypertension ; hff ; DASh ; srd ;target sodium
emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; hpEF ; non-diastolic abnormalities ; cardiovascular function
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent ; medical ; transplant
high-density lipoprotein ;HDl ; endothelial-protective ; endothelial cell ; nitric oxide
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
degs ; non-ischemic ; ischemic heart failure ; heart failure
insulin resistance ; diabetes ; insulin receptor substrates ; irs1 ; irs2 ; insulin-signaling ; metabolism
admission to discharge ; heart failure ; hz ; Nursing outcomes Classification ;NOc
8-fluo-cAMP binding ; phosphomimic Ser77 ; ser83 ; mutant ; RIα proteins ; double mutant ; wt RIα
albumin ; mortality ; lVAD implantation ;hazard ratio
systolic heart failure ; QRs ; ct ; rate of death ; hospitalization ; heart failure ; mortality
cox regression models ; propensity score ; oral glucocorticoid ; hz ; loop diuretics
functional electrical stimulation ; fes ; exercise capacity ; emotional ; endothelial function ; heart failure ; systolic function
dialysis ; hz ; mortality ; hz
bleeding ; driveline infection ; gastrointestinal bleeding ; stroke ; Rankin Score
Beta blockers ; mortality ; readmissions ; heart failure ; ejection fraction ; hbf ; heart rate ;HR
dyssynchronous HF ; electromechanical delay ; emd ; myocyte depolarization ; myofiber
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; ambulatory Heart Failure trial ;RAFt
biomarker studies
SAF ; abnormal liver ; nodularity
transplant ; pd ; hh ; volume management ; post-PD
frailty ; biological ; weak grip strength ; physical ; activity ; weight loss
ct-d ; icc ; ct-d
EDs ; discharge ; heart failure ; ED ; readmissions ; repeat ED visits
right heart failure ; therapy refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; ecmo ; cp ;ICU
report ; right atrial myxoma ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
heart disease ; hz ; palliation
heart magnetic resonance imaging ; chelation choices ; compliance ; heart failure ; arrhythmias
ejection fraction ; pre-PD ; NYha ; IIIb ; right ventricular dysfunction
cps ; early-outgrowth colony-forming units ; e-cfus ; circulating ; vgFR2
expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/ bax
nitroxyl ; hno ; Angeli ; inotropic ; lusitropic ; vasodilator effects ; cAMP
anticoagulation ; cardiovascular complications ; cardiovascular death ; acute heart failure ; atrial fibrillation ; af
evidence ; continuous-flow lVADs ; heartMate ; hm ; HeartWare ; bt ; dt
baseline
keletal muscle mass ; relative appendicular lean mass index
DASh ; diet scores ; mortality ; hh ; diet scores
mortality ; mortality
bNP ; bNP ; inhospital mortality
cardiovascular diseases ; heart failure ; hz ; hz
heart failure ; left ventricular systolic dysfunction ; BB
CLnka polymorphism ; heart failure ; glomerular filtration rate ; reNAStur
functional capacity ; hz
cardiac ; VEGF expression ; Akt ; endothelial NO synthase activation ; hearts
Gene expression profiling ; cultured cardiomyocytes ; jq1 ; drug abrogated ; induction ; phenylephrine-induced genes
exercise-induced PASp ; ventricular contractile reserve ; exercise-induced PASp
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; heart failure
cardiac ; insulin-resistance ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
baseline ; post-DASh ; srd ; brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
Psychosocial factors ; exercise ; Heart Failure ; Heart Failure ; exercise training
derivation cohort ; coronary angiography ; systolic HF ; etiology ;ejection fraction
arterial elastance ; end-systolic elastance ; ees ; ventricular-arterial coupling ; techniques
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic ; rhythm
cells ; angiotensin II ; angII ; hypoxia ; activators ; scn5a mRNA splicing ; induced ; scn5a
evidence ;HF ; ejection fraction ; hrEF ; treatment ;HF ; preserved ejection fraction ; hpEF
bridging therapy ; right heart failure ; refractory cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; exercise capacity ; endothelial function ; hpEF
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia ; noncardiovascular drugs
intubation rates
raloxifene ; mechanism of action ; heart failure
hearts ; tttMena ; mice ; heart mass ; transgenic mice
hFrEF ; exercise ; respiratory gas ; baseline
drugs ; heart failure ; biomedical
wasting of fat ; lean mass ; fat loss ; adipose tissue ;HF
hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
black race ; HF ; exercise ; HF ; mortality ; exercise training
adverse event rates ; acute myocardial infarction ; congestive heart failure
Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin ; hretn ; mRNA ; expression
lVADs ; CF ; HeartMate II ; thoratec Corp ; pleasanton ; calif ; hVAD ; HeartWare intl ; intl ; Framingham ; Mass
FM ; plasma NPs ; adiponectin ; baseline ; FM ; fm ; NPs ; adiponectin
sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
eh ; hfpEF ; hf ; hf ; therapy
collected ; hz ; immunoreactive ; NT-probNP ; NT-probNP
beat-to-beat QT interval ; eCGs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine infusion

power spectral ; low-frequency ; high-frequency ;LF ;HF ratio ; CHF-inv ; sham-inv ; sham levels ; DNx
contractility ; ventricular-arterial coupling
change ; follow-up visits ; readmissions ; hospital
natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
cardiac magnetic resonance ; hFPEF ; postcontrast ; biomarker ; hFPEF
left ventricular ejection fraction ; New York Heart association ; hz ; exercise
myocardial ; collagen deposition ; titin modification ; zSF1 ; rats ; heart failure ; ejection fraction
cardiac tissue ; mice ; sham-operated ; jq1 ; bet inhibition ; pathological cardiac gene expression programme
cox-proportional hazard models ; binomial regression models ; health
systolic blood pressure ; left ventricular ;LV ; hypertrophy
conditional gene-targeted hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene
cutoff value ; admission ; NT-probNP ; ed ; hz
Peak oxygen consumption ;VO2max ; HR ; bpm
follow-up ;heart failure ; sudden death ; noncardiac ; cardiac transplant
frailty ; health ABC Short physical performance Battery ; hABC Battery ; Gill index ; hh
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; hz
rule ; CAD ; angiography ; systolic HF ; cost
load-corrected chronotropic response ; heart rate ; exercise ; baseline ; follow-up tests ; heart rate ; exercise
hospital ; gastrointestinal bleeding ; ventricular tachycardia storm ; terminal heart failure
angioplasty ; stenting
hz ; t2d ;ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
hz ; QRs ; LVEF ; ct ; reverse remodeling ; LV ; systolic dysfunction
rv ; lVAD ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

frail ; frailty ; Gill index ; hz
HF ; am ; odds ratio
Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
β-AR stimulation ; catecholamine infusions ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac
chronic ; pAH ; rv ; rv ; pAH
zSF1 ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular
Xanthine oxidase ;XO ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
free-breathing pulse sequence ; myocardial t1 ; changes ; swine ; tachycardia-induced heart failure
pf ; New York Heart association
medication
physicians ; mortality ; physicians
western Australian ; administrative ; health ; hh ; am
report ; turkey
eds ; diagnosis ; heart failure ; ED
science ; treatment ; hz
miRNAs ; noncoding RNAs ; expression ; binding ; messenger RNA
HFpEF ; ivabradine
cardiac ; cardiac ; explant-derived cells ; cardiac functions ; myocardial infarction
NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
pathophysiology ; hf ; medical ; pathophysiologic state
heart failure ; hz ; acute myocardial infarction ;AMI ; pneumonia ; pna
mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor jq1 ; bets ; chromatin ; downstream ; RNA polymerase II ;Pol II
catheter ablation ; atrial fibrillation ; af ; heart failure ; ejection fraction ; hff
heart failure ; ejection fraction ; hpEF ; health
multivariate cox proportional hazards regression ; ie ; acute coronary syndromes ; coronary interventions
adenosine monophosphate ; cAMP ; guanosine monophosphate ; cgm ; hearts
RA ; methotrexate ; tNF antagonist ; antirheumatic drug ; nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
report ; ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; β1-adrenergic receptor ; g-protein-coupled receptors ; heart
septal ; pcWP
atrial fibrillation ; carvedilol ; metoprolol
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
ventricular function assessment
grls ; LVEF ; sa ; cv ; prognostic ; echocardiographic systolic ; AF
ERC induced recovery ; DAPc ; protein levels ; sarcomeric microstructure ; Skm ; myofibre regeneration
signalling cascades ; microRNAs ; expression ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene ; heart failure
rad Q66p ; inhibitory ; rad ; cav1.2 ; cav1.3 ; channel isoforms ; heart
EF ;LCx ; LAD ; stenting ; infarcted left ventricle ;LCx ; LAD
eh ; compliance ;LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg ; coefficient
mva ; surgical ring implantation ; leaflet motion ; edge-to-edge anastomosis
hART ; New York Heart association ;NYha ; hh ; self-management counseling ; primary outcome of death ; hh
cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
BET ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; hh ; pathogenesis ; hh
blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
grade
hz
foundation ; right heart circulatory failure ; mechanisms of disease ; right heart
voltage-gated ; ventricular action potentials ; trigger ; excitation-contraction ; coupling ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; ejection fraction ; hpEF
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
bp ; glomerular filtration rate ; hypertension ; transmitral ; diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; axis ; natural vasodilatory ; diuretic effect ; natriuretic peptides
β-blockade ; disease progression ; cAMP-dependent protein kinase ; pka ; downstream ; β-adrenergic receptor activation
evidence ; erythropoiesis-stimulating agent therapy ; venous thromboembolism
black race ; mortality ;hazard ratio ; cardiovascular mortality ; hospitalization
chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
genetic ; CHF ; genetic
peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; hh
heart failure ;HF ; tumor necrosis factor ; tbf ; tNF antagonists ; disease ; hf
Centers for Medicare and Medicaid services ; ms ; publicly ; mortality ; readmission rates ; penalties
follow-up ; physician ; discharge ; outcome ; death ; readmission
logistic regression ; rule ; CAD ; diameter stenosis ; CAD ; CAD ; proximal left anterior descending artery
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin
hff ; sodium-restricted DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
mechanism ; combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular dilatation
Randomized aldactone evaluation study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortality
heart failure ; acute myocardial infarction ; acute myocardial infarction ; western Australia
CHF ; ht ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication ; nonadherence
pathophysiological
lVAD ; surgery ; albumin levels ; hypoalbuminemia ; surgery
creatinine ;hazard ratio ; dl ; post-transplant mortality
glomerular filtration rate ;odds ratio
scientific ; hm ; HeartWare ; economic ; hm
dopamine ; nesiritide ; renal function ; acute heart failure ; renal dysfunction
HR variability ;turbulence ; HR variability ;turbulence ; cardiac patients
implantation ; lVAD ; transplantation ; bt ; dt ; medical
radial artery tonometry ; admission ; PH ;ICU
magnetically levitated centrifugal-flow chronic lVAS
signalling ; signalosome ; scaffold protein drives ; kinases ; sequential phosphorylation
Breast cancer ; Medicare coverage ; breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
ejection fraction ; natriuretic peptide ; heart failure ; inhospital outcomes ; get With the guideline-heart Failure Registry
cardiomyocytes ; pde2 activity ; cgMP ; nitric oxide donors ; pde2 inhibition
l-dko mice ; cardiac ; iRS1 ; iRS2 ; heart failure ; cardiac energy metabolism ; protein kinase
HDl ; phosphorylation ; eNOS-Ser ; eNOS- thr ; p70s6k-Ser
PASp
sts ; hm ; hm ; sts
mouse ventricular myocytes ; sarcomere ; transient
administrative ; Alberta ; discharged ; hospital ; heart failure
heart failure ; myocardial collagen ; heart failure
ct ; time to death ; hh ; hospitalization ;hazard ratio ; LVEF
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 ; cardiac gene therapy
relative risk ; r ; heart failure ; bisphophonates ; crude ; r ; hazard ratio ;HR
Medicare ; enrolled ; Centers for Medicare and Medicaid services
guideline ; heart failure ; Clinical practice guideline ; cpg ; heart failure ; hz
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic ; mitochondrial dysfunction ; antitumor activity
kccq ; New York Heart association ; hf ; hf
Rhythm control therapy ; af ; atrial ; sinus rhythm ; practice ; delayed rhythm control ; rate control
acute heart failure ; renal dysfunction ; dopamine ; low-dose nesiritide ; renal function ; diuretic therapy
hz ; body composition ; skinfold thickness ; dual-energy x-ray absorptiometry ; echocardiography ; blood testing
heart failure ; treatment
acp ; red blood cell transfusion ; trigger hemoglobin threshold ; hemoglobin levels ; coronary heart disease
heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia ; conditions
implanted ; left-to-right interatrial shunt ; haemodynamic ; heart failure ; ejection fraction
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; dt
Caloric restriction ; aerobic exercise ; Peak oxygen consumption ; Heart Failure ; ejection Fraction
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-ct trial ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
Oral glucocorticoids ; hh
HR ; ivabradine ; ea ;TAC
carvedilol ; metoprolol ;hazard ratio
ethnic groups ; CHm ; adjunctive treatment ; dc ; heart failure
testosterone ; exercise ; health outcomes ; CHF ; testosterone status
change ; peak VO2 ; change ; lean body mass ; change ; thigh muscle ; intermuscular fat ratio
guidelines-heart Failure ; hh
economic ; Patient management ; Heart failure ; cost-effectiveness ; disease management ; heart failure
HFPSI ; medical ; hh ; clinic outpatients ; hh ; health systems
cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
multivariate cox model ; PASp ; exercise ;hazard ratio ; peak o2 per kilogram ; PASp
pathophysiology ; heart failure ; ejection fraction ; hf ; myocardial extracellular matrix accumulation
mechanism ; combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ;pvf ; implanted ; cardioverter-defibrillator device
rad ; rg ; rem ; rem2 ; rad ; Gem ;Kir ; monomeric g proteins ; ventricular action potential ; coupling gain ; cardiac ; activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hz ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
Swedish Web-system for enhancement and development of evidence-based care ; Heart disease ; Therapies registry ; primary isolated caBG ; sweden
LVEF ; reverse remodeling ; time to death ; hz ;hazard ratio
brain natriuretic peptide ; bNP ; bNP ; bNP ; bNP
coprimary end points ; urine volume ; decongestion end point ; change ; serum cystatin c ; enrollment ;renal function
tpacse ; longitudinal rv fiber shortening ; PASp ;force ; rv ; length-force relationship
pde superfamily ; pde2 ; cgMP ; cAMP hydrolysis ; cross talk ; cgMP ; cAMP
probp ; t-probp ; midregional proANp ; m-proANp ; adiponectin ; CHF ; bmi ; FM
admissions
mitochondrial-targeted antioxidant ; Szeto-schiller ; SS20 ; cardiac function ; proteomic remodeling
financial ; cardiac arrest ; cardiopulmonary resuscitation ; cp ; posterior wall infarction ; cardiac
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ; hz
evidence ; acp ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin
uPR ; scn5a ; ventricular systolic ; hh ; induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers ; mortality ; readmissions
financial incentives ; cochrane Effective practice ; organisation of care taxonomy
coPD ; CHF ; crf ; icc ; kappa coefficients
stable heart failure ; left ventricular ejection fraction ; aerobic ; dynamic resistance training ; lower limbs
implantable ; cardioverter-defibrillator deactivation ; implant
heart failure ; myocardial function ; contracting ventricles
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
left ventricular longitudinal systolic strain ; grs ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ; af
mouse ; rad ; murine ; rad ; currents ; cav1.2 ; cav1.3 ; rad
MI ; hazard ratios ; hz
Medicare ; acute care hospital ; hz ;AMI ; pna
cardiovascular events ; baseline sST2 ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF ; abcs ; NRIs
HF ; HF ; EF ; HF ; change ; HF ; MI
phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
carvedilol ; von Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
mouse ; heart failure ;HF ; hypertensive heart disease ; hd ; pathophysiology ; hd
sarcoplasmic reticular ;SR ; protein ; SR ; phospholamban ; infarcted hearts ; metoprolol
temps up and go ; tug ; chronic obstructive pulmonary disease ; coPD ; chronic heart failure ;CHf ; chronic renal failure ; crf
exercise ; intramuscular testosterone supplementation ; chronic heart failure ; ghf ; testosterone ; health outcomes
hf ; LVEF ; long-term mortality ; LVEF ; LVEF ; long-term mortality
grs ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; cv
heart failure ;HF ; plasma ; natriuretic peptide ; bnp ; ejection fraction ;EF ; hz ; sex
RM ; home telemonitoring ; implanted monitoring devices ; medical ; ss ; contact ; hz ; hm
cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; acp ; shock therapy
ethically ; religious beliefs ; decisions
medical records
cost ; rhythm-control ; rate-control
left ventricular ejection fraction ; egFR
fit ; unfit ; cRF distribution ; hazard ratios ; fit ; unfit ; overweight ; body mass index ; obese
ct ; hazard ratio
hfPSI ; blood urea nitrogen ; natriuretic peptide ; New York Heart association ; diabetes ; atrial fibrillation
Medicare Patient Safety monitoring system ; mps ; adverse event rates ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
functional capacity ; cd34 ; vegFR2 ; cells ; peak VO2
treatment ; outpatients ; heart failure ; ejection fraction
case-fatality rate ; concurrent HF ; concurrent HF ; case-fatality rate
CHF ; anthracycline ; stem cell
Resting tension ; fpassive-sarcomere length ; muscle strips ; kcl-KI ; treatment ; titin ; extracellular matrix ; fpassive
reversibility ; heart failure ; myocardial infarction ; m ; β-adrenoceptor blockade ; infarcted ; metoprolol
aerobic ; resistance training ; exercise capacity ; muscle strength ; cardiac ;NT-ProbNP ; inflammatory ; il6 ; hscrp
hospital ; readmission ; all-cause readmission ; acr ; potential Preventable Readmission ; pPR ; Centers for Medicare and Medicaid ; 30-day readmission ; cms
congestive heart failure ; ed
exercise ; walking ; Minnesota ; quality of life ; exercise
arginine vasopressin ; aVP ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
physical ; implantable defibrillators ; circulatory ; transplantation ; heart failure ; disease
sodium-restricted dietary ; hypertension ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hff
right ventricular pacing ; gene expressions ; Bax ; bcl-2 ; Caspase-3 ; RTq- pcr ; interventricular septum biopsies ; beagle dogs ; heart failure
Rats ; hearts ; excised ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome ; bcl2 ; Bax ; caspase ; expression
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor
acute HF ; RELAx-aHF ;ASTRONAUT ; prONTO
hz ; international Classification of Diseases ; Ninth revision ; principal discharge
pulmonary capillary wedge pressure ; hg ; baseline ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
rad ; Q65p ; movement ; wild-type rad ; Q65p ; l-type channel inhibition ; rGK proteins
SS20 ; heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
New-onset aortic insufficiency ;AI ; mechanical circulatory ; flow ; left ventricular assist ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hh
follow-up visits
heart failure ; refractory ; terminal heart failure
heart failure ; university of Connecticut health Center ; follow-up visits
New York ; Heart association ; nyha ; Heart Failure ; eplerenone ; standard Heart Failure Medicines ;EMPhaSIS-HF
echocardiograms ; left ventricular base ; midpapillary ; baseline ; IVc occlusion ; BiVP ; ste ; twist ; basal rotations ; RS
evidence ; drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic ; endothelin ; vasopressin ; adenosine
hf ; induced ; mice ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-mig ; cardiac washout ; carvedilol ; metoprolol ; treatment ; β2-adrenergic receptor haplotype
treatment ; acute myocardial infarction ; am ; heart failure ; hz ; complicating ; am
h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; forkhead box ; impaired cardiac metabolic gene expression ; ATP
bottleneck stent ; implanted ; proximal left anterior descending ;LAD ; proximal circumflex artery ; lx ;LCx ; LAD ; pigs
postmarketing ; heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; inhibitors ; antihyperglycemic agents
multivariable cox modeling ; Heart Failure Patient Severity index ; hPSI ; university of Michigan ; hf ; clinic ;UM ; primary outcome
pde2 overexpression ; cardiomyocytes ; cAMP ; ca2 ; inotropic effect ; basal contractility
ATP ; shock therapy
Cardiac resynchronization therapy ; ct ; dialysis-dependent ; heart failure ; hz ; ct ; dialysis
joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ;HF mortality
eplerenone ; hyperkalemia ; renal function ; emphaSIS-HF ; eplerenone ; hospitalization ; Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; mechanism of cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ; avd ; interventricular delay ; vd ; ste ; radial strain ;RS
New York Heart association ; nyha ; functional class III ; hh ; ejection fractions ; chronic ; guideline-directed medical therapy ; ght ; united states ; Canada ; europe
non-LBb ; QRs ; hazard ratio ; primary outcome ; QRs ; hazard ratio
dyssynchronous HF ; myofiber ; velocity ; septum ; myofiber ; stretch rate ; late-activated lateral wall
label-free shotgun proteomics ; proteomics ; transverse aortic constriction ;TAC ; heart failure
transforming growth factor-β ; tgf-β ; epithelial ; mesenchymal transition markers ; expression of pluripotency markers ; shams
pka ; change ; regulatory ; riiα ; expression ; phosphorylation ; hz
hf ; left ventricular ejection fraction ; hfpEF ; left ventricular ejection fraction ; β-blocker dose changes ; hf
cross talk ; g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; chronic β-adrenergic receptor ; postischemic heart failure
concentric remodeling ;cr ; concentric hypertrophy ; left ventricular ;LV ; remodeling ; heart failure ; ejection fraction ; hpEF ; eccentric hypertrophy ;EH
Body ; exercise ; exercise ; diet
RV ; cachexia ;hazard ratio
resting HR ; follow-up ; baseline ; VO2max ; resting HR
tgg-β inhibition ; c-Kit ; cell phenotype ; cardiac progenitor function ; cell expansion protocols
NT-probNP ; inflammatory biomarkers ; hscrp ; il6) ; hscrp
BETs ; in vitro model ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; burden of heart failure ; hospitalizations ; ght-treated NYHA ; functional class III HF
activation ; p70s6k ; PKc-βII ; malondialdehyde ; bound ; HDl ; HDl
mlf ; exercise ; diet ; exercise ; diet
nonpace ; ham-innervated ; ham-inv ; nonpace ; ham-dx ; pace non-DNx ; cmf-inv ; pace DNx ; cmf-DNx
hbc Battery score ; hz ; health ; ABC ; hz ; death
ejection fraction ; frail ; biological phenotype ; frailty ; deficit index ; death
hemoglobin ; hgb ; HRQol ; HRQol ; Heart Failure ; exercise training
atrial Fibrillation ; congestive Heart Failure ; health care ; expenditures ; Québec ; rhythm ; rate-control ; treatment
heart failure ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
report ; calcineurin ;fat signalling ; mir-25 expression ; basic helix-loop-helix ; bHLh ; transcription factor ; hand ; mouse ; myocardium
exercise time ; psss ; btes ; exercise time ; pss ; btes
NT-probNP cutoff point ; admission
prognostic power ; HR ; fractal scaling exponent
diastolic function ; diastolic filling ; relaxation ;viscoelastic ; passive ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ;HF ; vt ; structurally normal hearts ; hNorm
grs ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke score ; glomerular filtration rate ; LVEF ; cv
VAD ; ventricular assist device ; ecmo ; extracorporeal membrane oxygenation membrane ; ecmo ; VAD
ischemic events ; ies ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; crt-d
heart failure disease management ; evidence-based treatments ; health care system
resistin ; heart failure ; mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers
TTA ; tgtetMena mice ; cardiac injury ; ejection fraction ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; ambulatory Heart Failure trial ; implantable ; cardioverter defibrillator-ct ; primary end point ; mortality ; heart failure
heart failure ; italy ; confirmatory factor analysis ; cfa ; schfi ; self-Care Maintenance ; Self-Care management ; Self-Care Confidence
functional ; mwt ; NYha ; HFpEF ; hFrEF ; therapy ;HFpEF ; death ; hf
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; cardiomyopathy
Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
CHF ; testosterone ; exercise ; testosterone
functional MS ; dynamic ; LV dilatation ; treatment ; heart failure ; hz ; LV ; functional ; ms ; hz ; MR ; prolapse ; mitral valve
New York Heart association ; kccq ; Spearman ; HF ; EF ; hpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure ; medications ; medical records
c57b ; infusion ; ang II infusion ; uninephrectomy ; ANG II infusion ; salt loading ; ANG II infusion ; uninephrectomy ; salt loading
early transmitral blood flow velocity ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; systolic heart failure ;HF
systolic indices ;LV ; ejection fraction ; strain ; strain rate ; systole ; diastolic indices ; strain rate ; diastole ; transmitral flow ; sinus rhythm
peak VO2 ; exercise ; body mass ; diet ; body mass
hazard ratios ; confidence interval ; early-onset HF ; late-onset HF
AMI ; hospital ; hospital ; odds of dying
Mass spectrometry ; circulating ; NT-probNP ; physiological proteolysis
ctnt ; NT-probNP ; report ; ctnt ; NT-probNP ; hh prediction model
hpEF ; New York Heart association ; mean ejection fraction ; fes
depressed left ventricular ;LV ; systolic pressure ; ejection fraction ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
baroreflex activity Therapy ; Heart failure ; ejection Fraction ; carotid ; baroreflex activation therapy ; advanced heart failure ;HF
enrollment ;hazard ratio
la ; hf ; risk factors ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; la
cRF ; overweight ; obese body mass index
kccq ; hbfpEF ;log ; EF
baseline ; egFR ; egFR ; egFR ; hypertension ; diuretics ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ; hz ; pde2 ; beta-adrenergic receptor ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable ; cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm mitochondrial ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; maisel ; Henry
follow-up ; urgent readmission
mena overexpression ; TTA ; mice ;TAC ; surgery ; Mena levels ; cardiac hypertrophy ; TTA ; TAC ; cardiac
echocardiography ; LV ; end-diastolic volume ; ml ; m2 ; MR ; mitral valve opening ; mva ; pressure gradient ; hg
p ; diuretic refractory ; hf ; prelated complications
ATP production rates ; post-aac ; mitochondrial oxidation ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association ; heart failure ; hz ; ventricular ejection fraction ; permanent periodic breathing ; pb ; report
implantation ; bottleneck stent ; proximal LAD ;LCx ; reversible myocardial ischemia ; open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; AAs ; race ; treatment
obese ; body mass index ; chronic ; hFPEF
proangiogenic effects ; VEg pathway ; injected ; adenoviral vector ; veg receptor ; ad-flk ; adenovirus ; ad-c
surgery ; post- lVAD ; AI ; aortic valve ; leaflet repair ; bioprosthetic ; aortic valve replacement ; CF lVAD ; AI
pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
MEDline ;EMBAse ; healthstar ; nahl ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institute of evidence based practice ; evidence based practice
health care systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; ste ; rvpo ; RS synchrony ; biVP
tAPse ; PASp ; tAPse-to-PASp ratio ; tpacse ; pasp ; cox regression ; kaplan-meier analyses ; tAPse ; PASp
cPET ; CHF ; exercise ; exercise ; exercise
heart failure ; mRNA splicing ; voltage-gated cardiac ; scn5a ; truncated ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; malignant disease
economic ; Heart Failure ; cost-effectiveness model ; evidence-based medications ; costs
natriuretic peptides ;NPs ; acute heart failure ; Emergency department ; ed ; acute dyspnea
peak oxygen consumption ; peak VO2 ; vco2 slope ; exercise ; exercise oscillatory ventilation ; eOV ; end-tidal co2 ;PETco2 ; cardiopulmonary exercise testing
denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; ms ; mitral valve ; organic lesion ; systolic ; diastolic tethering ; functional etiology ; ms
tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; diuretic therapy ; sodium levels ; systolic function
longitudinal strain ; left ventricle ; echocardiographic ; baseline echocardiography ; ct ; follow-up echocardiograms
platelet-activating factor ;paf ; metabolic enzymes ; heart failure ; bmi-matched
acute care surgery ; acs ; oHT ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
hpEF ; ivabradine ; exercise capacity ; left ventricular ; filling pressure ; exercise ; diastolic mitral flow velocity ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ; raas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; hbfpEF
lVET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ;RAS blockers ; β-blockers
cardiac ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers therapy
SS31 ; congestive heart failure phenotypes ; mitochondrial damage induced ;TAC ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ; ATPase activity ; mRNA levels ; SR ; ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA ; β-myosin heavy chain ; metoprolol
HDl ;HDl ; healthy ; CHF-NYHA-III ;HDl ; CHF-NYHA-II ;HDl
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular ; end-diastolic pressure ; myocardial oxygen ; ejection fraction ; ventricular power index
md ; mdc ; mdc ; confidence level ; mdc
baseline ; heart failure ; administration ; contrast agent ; administration
etiologies ; hz ; la ; dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 levels ; functional capacity ; ambulatory patients ; hh ; Heart Failure ; exercise training ; hh
report ; cardiopulmonary exercise testing ; exercise rehabilitation ; chronic heart failure ; exercise rehabilitation ; chronic heart failure ;CHf ; CardioPulmonary exercise testing ; cPET ; exercise rehabilitation ; China
AA ; ischemic HF pathogenesis ; NYHA ; functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
hz-action ; exercise training ; hz ; left ventricular ejection fractions ; HRQol ; Kansas City Cardiomyopathy Questionnaire ; kvcq ; baseline
ct ; systolic dysfunction ; resynchronization reverses remodeling ; systolic left v entricular dysfunction ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egFR ; diabetes ; cholesterol ; lDL-cholesterol ; CLcnka GG
echocardiography ; end-diastolic ; LV ; end-diastolic pressure ;wall stress ; lung weight ; ecb ; sham group
diagnostic
spironolactone ; death
cardiac procedures ; driven ; cardioversions ; costs ; antiarrhythmic drugs ; confidence interval
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy and survival study ; eheSUS ; post-myocardial infarction ; heart failure ; mortality ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-ct ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
heart failure-related mortality ; sudden death
DASh ; srd ; brachial systolic pressure ; central end-systolic pressure
hf ; obese ; body mass index ; black ethnicity ; cardiomyopathy
mortality ;HF ; LVEF ; Heart Failure Survey ; israel
left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography
european society of Cardiology ; hff ; heart failure ; ejection fraction ; left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
β1ARs ; s1PR1s ; myocyte ; cAMP production ; report ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
PAf-cp ; PAf ; lyso-paf-AT ; PAf-AH ; lp-PLA2
heart failure ; ejection fraction ; cardiac rehabilitation ; nordic walking ; exercise
dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; sarcopenic range ; muscle wasting ; t-score ; significant wasting ; t-score
exercise ; testosterone ; baseline ; peak oxygen uptake ; Beck depression inventory ; leg strength ; medical ; Short-Form quality of life ; exercise
mortality ; hf ; readmissions ; hfrf ;hazard ratio ; confidence interval
Heart Failure ; exercise training ; hh-action ; exercise ; psss ; barriers to exercise ; btes
ST2 ; cardiovascular ; death ; hz ; hospitalization ;hazard ratio ; mortality ; hazard ratios
New York Heart association ; cardiopulmonary exercise ; lean mass ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
dopamine ; nesiritide ; diuretic ; renal function ; acute heart failure ; renal dysfunction
ct ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ;HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
baseline ; hz ; activities ; lyso-paf-AT ; PAf-cpt ; PAf ; activities ; PAf-AH ; lp-PLA2
medical ; sternotomy ; aortic valve ; bioprosthetic ; valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter ; aortic valve ; open surgery ; aortic valve replacement
cutoff value ; natriuretic peptide ;NT-probNP ; acute heart failure ; hz ; emergency department ; ed
cardiac troponin t ; ctnt ; high-sensitivity assay ; natriuretic peptide ;NT-probNP ; biomarkers ; hh ; hh ; Atherosclerosis Risk in communities ;ARIc
body mass index ; event rate ; fat mass ; fat-free mass index
interquartile range ; body mass index ; interquartile range ; COPd ; CHF ; crf
reverse remodeling ; ejection fraction ; mortality ;HF ; dialysis patients
eh ; contractility ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ; hg
echocardiography ; ejection fraction ; MR ; mitral valve opening ; ms ; mva ; pressure gradient
acute heart failure ; renal dysfunction ; glomerular filtration rate
molecular analysis ; bets ; chromatin-mediated signal transduction ; pol II ; co-activating transcription factor networks ; hh pathogenesis ; nuclear factor ; activated t cells ; naFAT ; nuclear factor-κb ; transcription factor
guideline ; mortality ; exercise ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ;ischemic cerebrovascular events
cardiovascular mortality ; hazard ratio ; hazard ratio
EO-cfus ; diabetes ; diabetes ;EO-cfu ; peak VO2 ; diabetes ; EO-cFUs ; peak VO2
immunoblotting ; radioenzymatic ; fluorescence resonance energy transfer-based assays ; edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; hz
east ; atrial fibrillation ; stroke prevention trial ; onset AF ; stroke ;CHA2s2VASc ; rhythm control therapy ; blinded outcome assessment trial
exercise capacity ; peak oxygen consumption ;VO2 ; Qol ; Minnesota Living with Heart Failure ; mlh ; Questionnaire ; heart failure ; Qol
TAC-induced proteomic ; mitochondrial-targeted peptide ; SS31 ; perturbed mitochondrial function ; upstream signal ; pathway ;TAC ; mitochondrial-targeted peptide ; drugs ; heart failure
left ventricular ejection fraction ;HF ; left ventricular ejection fraction ; hospital ; physicians ; outpatient settings ; medical ; financial costs
hf ; left ventricular ;LV ; ejection fraction ; hpEF ; echo-doppler ; pro-brain-type natriuretic peptide
eds ; hospitalized ; high-volume EDs
cardiac transplant ; ect ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
hbc Battery scores ; health ; ABC HF Risk model ; discrimination ; c-index ; HF
cfi ; RMsea ; Self-Care Maintenance Scale ; cfi ; RMsea ; Self-Care management Scale ; cfi ; RMsea ; Self-Care Confidence scale
BAT ; quality-of-life ; NYha ; functional class ranking ; change in distribution
hypoalbuminemia ; postoperative ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; cardiomyopathies ; implantable ; cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist devices
SAF ; pf ; catheterization ; central venous pressure ; hg ; srv ; dyn ; cardiac index
admission ; bnp ; EF ; bnp ; borderline
heart failure ; admission ; heart transplantation ;LV ; assist device ; death ;hazard ratio ; death
ejection fraction ; velocity of circumferential shortening ; systolic elastance ; contractile efficiency ; acf ; aCF ; allopurinol rats ; o2 consumption rate ; cardiomyocytes ; extracellular flux analyzer
hfpEF ; LV ; hypertrophy ;LVh ; relative wall thickness ; rwt ; LVh ; rwt ;LVh ; rwt ; eh ;LVh ; rwt
lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; ejection fraction ; heart failure ; ejection fraction
blood pressure ; mitral valve plasty ; MR ; prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring ; edwards lifesciences ; irvine
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; minnesota Living with Heart Failure Questionnaire ; medical
term ; LVEF ; mortality ; LVEF ; age-by-LVEF
westar-kyoto ; lean ; zSF1 ; obese ; zSF1 ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
kaplan-meier curves ; log-rank testing ; UM ; va-RT
multivariate cox regression ; AF ; af ; hypertension ; sinus rhythm ;hazard ratio ; confidence interval
chronic HF-ref ; NYha ; functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
body composition ; fm ; FM ; body fat distribution ; dual energy ; x-ray absorptiometry ; dXA ; chronic heart failure ;CHf ;cc ; CHF ; myocardial infarction-both
baseline ; drug dose ; spironolactone ; end point of death ; hz ;hazard ratio ; AAs ;hazard ratio
pulmonary arterial hypertension ; chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; hz ; btes ; borderline association ; btes ; cardiovascular death ; hz ; exercise ;hazard ratio
index ED ; low-volume ED cases ; death ; readmission ; aOR ; high-volume EDs ; aOR
implantable cardioverter-defibrillator deactivation ; implantation ; mind ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; atrial area ; pulmonary vascular resistance ; cardiac events
hh ; systolic ; left ventricular ejection fraction ;HF ; conditions ; New York Heart association ; echocardiographic ; cardiopulmonary exercise
heart failure ; ABCd ; American college of Cardiology ; acc ;American Heart association ; ha ; New York Heart association ; nyha ; structural heart disease ; heart failure ; medical ; treatment
mva ; end-diastolic volume ; end-systolic volume ; mitral filling flow ; mva ; velocity time ; mitral filling flow ; doppler echocardiography ; MR ; mitral valve plasty
statitistical significance ; RM ; all-cause mortality ; sts ; hz ; cr ; Cr
HFPSI ; Ann arbor ; Veterans ; affairs ; HF ; clinic ; va ; hPSI ; va-RT ; va ; HFPSI
AAs ; spironolactone ; hyperkalemia ; hypokalemia ; potassium
LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF ; LVEF
hpEF ; primary outcome ;odds ratio ; nyha ; walk test ; mwt ; medications
pulmonary arterial systolic pressure ;PASp ; right ventricular ;rv ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
CAD ; diabetes ;odds ratio ; electrocardiographic ; waves ; left bundle branch block ;odds ratio ; nondiabetes ; risk factors ; dyslipidemia ; hypertension ; tobacco ;odds ratio
receiver ; operating characteristic curve ; pcWP ;septal
trastuzumab-treated ; coronary artery disease ; hypertension ; trastuzumab administration ; CHF
LVEF ; clinical composite response ; ct ; ct OFF ; LV ; end systolic volume index ; ml ; mass
tgf-β signaling ; tgf-β receptor ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
hfrf ; diuretics ; mwt ; mwt ; NYha
surgery ; hz ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mva ; pressure gradient
systolic heart failure ; ecection fraction ; ivabradine ; SHIft ; systolic Heart failure ; treatment ; if inhibitor ivabradine trial ; ivabradine ; echocardiographic
Hazard ratios ;hazard ratio ; pib ; New York Heart association ; functional class
Renal function ; Chronic Kidney Disease Epidemiology ; glomerular filtration rate ; egFR ; mL ; mL
paradigm-HF ; chronic heart failure ; systolic dysfunction ; vn ; functional ; nyha II-III ; bn ; primary endpoint ; cardiovascular death ; hospitalization ; heart failure ; arni ; lz696 ; sacubiltril ; valsartan
LV reverse remodeling ; pre-ct ; LV ; end-diastolic ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area ; right atrial area ; right ventricular fractional area change
hyperkalemia ; African Americans ; white ; New York Heart association ; nyha ; hz ; left ventricular dysfunction ; spironolactone ; Randomized aldactone evaluation study ;RALes
iRS1 ; iRS2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; iRS2 ; heart-specific ; iRS1 ; iRS2 ; double-knockout ; h-dko ; mice ; liver-specific ; iRS1 ; iRS2 double-knockout ; l-dko
b-type natriuretic peptide ; natriuretic peptide ; stable coronary artery disease ; b-type natriuretic peptide ; bNP ; n-terminal fragment ;NT-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range
Therapy ; ivabradine ; change ; diastolic mitral flow velocity ; diastolic mitral annular velocity ; exercise capacity ; therapy ; ivabradine ; oxygen uptake
liberal transfusion ; mortality rates ; i2 ; mortality rates ; acute coronary syndrome
readmission ; hazard ratio ; physician ; follow-up visits
hek ; embryonic kidney ; sphingosine-1-phosphate ; s1PR1 ; agonist ; isoproterenol ; β-adrenergic receptor agonist
baseline ; walked distance ; kansas City ; Cardiomyopathy Questionnaire ; Minnesota ; Heart Failure Questionnaire ; depressive ; beck depression inventory ; zung ; depression scores ; natriuretic peptide ; endothelial function ; flow-mediated dilatation ; ventricular diastolic function
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; acute kidney injury
diastolic function ; ea ; ventricular-arterial coupling
hazard ratios ; disease risk score ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
coronary artery bypass surgery ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
biomedical treatment ; biomedical treatment ; CHm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
masked outcome assessments ; stable heart failure ; ventricular ejection fraction ; arg16 ; grln27 ; gly16 ; lu27 ; haplotype ; β2-receptor ; carvedilol ; metoprolol
ed cases ; death ; ed ; aOR ; aOR ; high-volume ED cases ; aOR ; aOR
health Buddy program ; mortality ;hazard ratio ;HR ; confidence interval ; inpatient admissions ; baseline
multivariable-adjusted hazard ratios ; DASh ; diet score
ctnt ; NT-probNP ;laboratory report ; aRIC ; hz ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hz ; receiver operating characteristic curve ; auc ; discrimination improvement ; net reclassification improvement ; nrri
eplerenone ; hyperkalemia ; renal function ; wr ; emphaSIS-HF ; heart failure ; ejection fraction ; hz-ref ; New York Heart association ; nyha ; functional class II ; glomerular filtration rate ; egFR ; serum potassium
nesiritide ; urine volume ;nesiritide ; change ; cystatin c level ;nesiritide
nordic walking ; functional capacity ; mwt ; physical ; activity ; right grip strength ; depressive ; hospital anxiety and depression Scale
hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ; potassium ; hyperkalemia ; wRF ; primary outcome ;hospitalization ; hz ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ; dithiothreitol ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; catabolic isoenzymes ; PAf-acetylhydrolase ; lipoprotein-associated phospholipase a2 ; leukocytes
ivabradine ; baseline ; follow-up exercise capacity ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; early diastolic mitral annular velocity
CHF ;Odds ratio ; ht ; chest radiation ; hypertension ; genes coding ;NAD ; h-oxidase subunit RAC2 ; hfe ; doxorubicin efflux transporter
baseline ; follow-up ; NYha ; change ; Duke activity status index ; Kansas City ; Cardiomyopathy Questionnaire ; walk test distance
dopamine ; urine volume ;dopamine ; change ; cystatin c level ;dopamine
baseline glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF ; mortality
peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City ; Cardiomyopathy Questionnaire ; Minnesota ; living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes ; natriuretic peptide ; mitral ; wave ratio
